Business Context and Reporting Period
This Form 8-K, filed on March 6, 2011, by Accuray Incorporated (Accuray), reports the entry into a Material Definitive Agreement. On this date, Accuray entered into an Agreement and Plan of Merger with TomoTherapy Incorporated (TomoTherapy) and Jaguar Acquisition, Inc., a wholly owned subsidiary of Accuray. The transaction proposes that TomoTherapy will merge with and into the subsidiary, surviving as a wholly owned subsidiary of Accuray.
Key Financial Metrics and Transaction Terms
The filing details the consideration for the merger rather than standard operating financial metrics such as revenue or profit for the period.
- Merger Consideration: Each outstanding share of TomoTherapy common stock will be converted into the right to receive $3.15 in cash and 0.1648 shares of Accuray common stock.
- Equity Treatment: Outstanding TomoTherapy stock options will convert to Accuray options based on a specific exchange ratio formula involving the volume-weighted average price of Accuray stock.
- Restricted Stock: Restricted stock will receive the same consideration, though the cash portion is deferred until the original vesting schedule is met.
- Termination Fees: TomoTherapy is required to pay a termination fee of $8,000,000 if the agreement is terminated under certain circumstances. In other termination scenarios, TomoTherapy may be required to pay Accuray's expenses up to $1,500,000.
- Cash Deposit Condition: Completion requires TomoTherapy to deposit $65,000,000 in cash into an account with the exchange agent.
The filing text does not provide clear values for Accuray's or TomoTherapy's current revenue, profit, cash flow, margins, or debt levels.
Material Changes and Conditions
The primary material change is the proposed acquisition of TomoTherapy. The transaction is subject to several closing conditions, including:
- Approval by TomoTherapy's shareholders.
- Receipt of antitrust approval (Hart-Scott-Rodino Antitrust Improvements Act).
- Receipt of certain third-party consents.
- Deposit of the $65,000,000 cash requirement.
Concurrently, TomoTherapy's executive officers and directors entered into a Support Agreement to vote their shares (representing approximately 11% of outstanding stock as of February 28, 2011) in favor of the merger.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated strategic and financial benefits, synergies, and economies of scale. However, it explicitly states that investors should not put undue reliance on these statements.
Key Risks and Contingencies:
- Failure to satisfy closing conditions, including antitrust clearance.
- Market conditions and the effect of the announcement on ongoing operations.
- Risk of failure to complete the transaction or realize anticipated benefits.
- Potential inability to successfully integrate TomoTherapy's business.
- General industry and economic conditions.
The filing notes that this report is not a substitute for the proxy statement or registration statement that will be filed later.
Important Facts for Investor Verification
- Verify the final approval status of the merger by TomoTherapy shareholders and regulatory bodies.
- Confirm the volume-weighted average price of Accuray stock used to calculate the final stock option exchange ratio.
- Review the upcoming proxy statement and registration statement for detailed financial projections and risk factors.
- Monitor the status of the $65,000,000 cash deposit requirement by TomoTherapy.
- Assess the potential dilution impact of issuing 0.1648 shares of Accuray stock for each TomoTherapy share.